BPMC vs. RETA, FOLD, MRVI, IMGN, CYTK, RARE, PTCT, ZLAB, AXSM, and PRTA
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Reata Pharmaceuticals (RETA), Amicus Therapeutics (FOLD), Maravai LifeSciences (MRVI), ImmunoGen (IMGN), Cytokinetics (CYTK), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Axsome Therapeutics (AXSM), and Prothena (PRTA). These companies are all part of the "pharmaceutical preparations" industry.
Blueprint Medicines vs.
Reata Pharmaceuticals (NASDAQ:RETA) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends.
Reata Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Reata Pharmaceuticals has higher earnings, but lower revenue than Blueprint Medicines.
Blueprint Medicines has a net margin of -284.02% compared to Reata Pharmaceuticals' net margin of -9,897.91%. Blueprint Medicines' return on equity of -100.31% beat Reata Pharmaceuticals' return on equity.
76.1% of Reata Pharmaceuticals shares are held by institutional investors. 26.8% of Reata Pharmaceuticals shares are held by company insiders. Comparatively, 3.9% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Blueprint Medicines received 151 more outperform votes than Reata Pharmaceuticals when rated by MarketBeat users. Likewise, 68.62% of users gave Blueprint Medicines an outperform vote while only 66.34% of users gave Reata Pharmaceuticals an outperform vote.
In the previous week, Blueprint Medicines had 12 more articles in the media than Reata Pharmaceuticals. MarketBeat recorded 17 mentions for Blueprint Medicines and 5 mentions for Reata Pharmaceuticals. Reata Pharmaceuticals' average media sentiment score of 0.80 beat Blueprint Medicines' score of -0.04 indicating that Reata Pharmaceuticals is being referred to more favorably in the media.
Reata Pharmaceuticals presently has a consensus target price of $99.89, indicating a potential upside of 6.49%. Blueprint Medicines has a consensus target price of $74.89, indicating a potential upside of 28.08%. Given Blueprint Medicines' higher possible upside, analysts clearly believe Blueprint Medicines is more favorable than Reata Pharmaceuticals.
Summary
Blueprint Medicines beats Reata Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
